UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions from Phase 1 Part A and preclinical studies, and support advancement of UB-312 into further cl.
Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) and Vaxxinity (NASDAQ:VAXX – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk. Insider and Institutional Ownership 65.5% of Arrowhead Pharmaceuticals shares are owned […]
Indaptus Therapeutics (NASDAQ:INDP – Get Rating) and Vaxxinity (NASDAQ:VAXX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Institutional and Insider Ownership 6.9% of Indaptus Therapeutics shares are […]